Introduction
In France, health insurance coverage is mandatory for all individuals. Administrative information necessary for the reimbursement of healthcare costs by French National Health Insurance is recorded in the Vitale Card that patients use in every step of their care. Since 2013, this information is available in claims database including for each patient the comprehensive history of his/her health care expenditures. This database can be accessed alone or through a linkage to an electronic medical record database. The objective of this study was to evaluate the usefulness of this newly accessible information in assessing treatment cost of Benign Prostatic Hyperplasia (BPH).
Conclusions
By using the newly available IMS RWE Reimbursement History database (RH) linked to IMS Real-World Data EMR-France (LPD), we were able to estimate an average cost for HBP in France of 160 euros/patient/year. At the time of the study, the RH was under construction which explains the small number of patients available. Estimating costs related to therapies is an increasingly mandatory exercise for pharmaceutical companies. The combination of EMR and claims allows a relevant and accurate analysis of health care costs from the payer's point of view.
Study Population
Database: We used a longitudinal primary care electronic medical records database (Longitudinal Patients Database, LPD, now IMS Real-World Data EMRFrance) linked to the administrative claims database of the mandatory National Health Insurance through IMS RWE Reimbursement History database (RH), via a unique, encrypted and anonymized personal number assigned to patient. Cohort: One cohort of patients was selected according to their treatment in Benign Prostatic Hypertrophy (BPH) (G04C). All patients initiated by one of the defined anti BPH treatments and never having received treatment for BPH before in the entire available history (means first intention) were included. The inclusion criteria were all patients prescribed a BPH treatments, Aged more than 18 years at the index date, with a minimum of 1 year in the LPD database before index date and with at least one visit to their general practitioner (GP) after the index date (whatever the motive of the visit to GP). However, all patients with a free or fixed combination therapy at index date and Women were excluded from the analysis. 
Data Collection
Data collected during the study period : sociodemographic characteristics, medical history of patients, and healthcare resource use due to BPH. For all medical resources consumption during one year after the GP treatment initiation visit, data were provided by GPs through the medical record software. The health effects are identified and measured from the perspective of individuals affected by the interventions. Related diagnosis selected from the electronic medical records database :
• Hypertension.
• Diabetes.
• Urinary history • Comorbidity treatment for contra-indications of G04CA/G04CB 
Statistical Methods
Resources consumption and mean annual costs were a n a l y ze d . A d e s c r i p t i ve a n a l y s i s wa s c a r r i e d o u t distinguishing patients according to treatments. Secondarily, multivariate regression analyses were used to explore the relationships between costs associated covariates. The associated covariates included in the models were the demographic and clinical variables (age, gender, comorbidities, past history diagnosis, smoking status, hospitalization, ambulatory exams, drugs). Economic evaluation for the calculation of costs were made for each patient based on consultations and prescriptions observed during the study period of one hand and reimbursement related to the pathology and performed during the year. Only patients with RH available data were taken into account in the cost analysis. Medical resource consumptions and costs were annualized and described. The cost analysis was carried out according to a payer's point of view that was sufficiently broad to take into account all stakeholders concerned by the treatments studied, and considered direct costs only. From the French health system and accordingly to national guidelines, a unit cost was given to each item according to the tariff currently used in 2013. Unit costs data were extracted from official tariffs for ambulatory care and national costs estimates for hospitalization (1) . All costs were expressed in Euros for year 2013 (1 US$ = 1.37 Euro). Of note, sick leaves refund were not considered given the fact that the analysis focuses on these newly diagnosed patients. Moreover, refund of transport was not considered because the analysis is based on primary care physicians and therefore distances to access to primary care are less than when one is interested in specialists the French healthcare systems. The study was designed to collect as exhaustively as possible data on health-care consumption of BPH patients for 1 year. The reference case analysis uses a time horizon which is long enough to reflect all expected consequences in costs and health effects between the interventions being compared. As data were collected over the first year of treatment, cost data were not discounted. 
